Building Evidence for Ablative Internal Radiation Therapy in Localized HCC Beyond the Up-To-7 Criteria

At four major centers in Korea, patients with hepatocellular carcinoma (HCC) that exceed the up-to-7 criteria yet remain locally confined will undergo ablative radioembolization using Yttrium-90 glass microspheres, guided by a standardized dosimetry method. Their treatment response, survival outcomes, and adverse events will be monitored for two years following the procedure.

Trial Details

NCT ID
NCT06773845
Phase
PHASE2
Sponsor
Seoul National University Hospital
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • TheraSphere
Locations (sample)
  • Gangneung, Gangwon-do, South Korea|37.75266,128.87239
  • Anyang-si, Gyeonggi-do, South Korea|37.3925,126.92694
  • Ilsan, Gyeonggi-do, South Korea
  • Seongnam-si, Gyeonggi-do, South Korea|37.43861,127.13778
  • Seoul, South Korea|37.566,126.9784

Key Eligibility Criteria

  • Adult aged 19 and over
  • HCC diagnosed by histology or non-invasive criteria of the American Association for the Study of Liver Disease
  • Unresectable HCC beyond the UT7 criteria: the sum of the diameter of the largest tumor (cm) and the number of tumors \> 7
  • Localized HCC: all tumors are in the one to five geographically adjacent Couinaud segments

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →